CYP3A4 active site volume modification by mutagenesis of leucine 211.

被引:22
作者
Fowler, SM
Taylor, JM
Friedberg, T
Wolf, CR
Riley, RJ
机构
[1] AstraZeneca R&D Charnwood, Phys & Metab Sci, Loughborough, Leics, England
[2] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland
关键词
D O I
10.1124/dmd.30.4.452
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The leucine 211 --> phenylalanine (L211F) and feucine 211 --> tyrosine (L211Y) mutant forms of cytochrome P450 3A4 have been generated by site-directed mutagenesis and expressed functionally in Escherichia coli. Substrate binding affinities (S-50 values) for testosterone and 7-benzyloxy-4-trifluoromethylcoumarin (BFC) were similar for the mutants and wild-type CYP3A4 (49 and 21 MM for L211F, 35 and 20 muM for L211Y, and 33 and 20 muM for the wild type, respectively). For erythromycin, however, the K-m values determined for the L211F and L211Y mutants were 2.4- and 10.5-fold higher thin for the wild type. Furthermore, IC50 values for the inhibition of testosterone 6beta-hydroxylation by erythromycin and troleandomycin for L211F were 2.4- and 3.7-fold higher, and those for L211Y were 3.4- and 9.2-fold higher than those measured for the wild type. Conversely, small inhibitors, such as diazepam, exhibited no significant difference in IC50 values between the wild type and the L211F and L211Y mutants. It is proposed that large substrates bound in the catalytic center of CYP3A4 with molecular volumes greater than similar to600 Angstrom(3) were less well accommodated in the altered active sites, resulting in lower association energies and increased IC50 values.
引用
收藏
页码:452 / 456
页数:5
相关论文
共 16 条
[1]   Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli [J].
Blake, JAR ;
Pritchard, M ;
Ding, SH ;
Smith, GCM ;
Burchell, B ;
Wolf, CR ;
Friedberg, T .
FEBS LETTERS, 1996, 397 (2-3) :210-214
[2]  
Busby WF, 1999, DRUG METAB DISPOS, V27, P246
[3]  
Chauret N, 1998, DRUG METAB DISPOS, V26, P1
[4]   Amino acid 305 determines catalytic center accessibility in CYP3A4 [J].
Fowler, SM ;
Riley, RJ ;
Pritchard, MP ;
Sutcliffe, MJ ;
Friedberg, T ;
Wolf, CR .
BIOCHEMISTRY, 2000, 39 (15) :4406-4414
[5]   Synthetic strategies to lower affinity for CYP2D6 [J].
Halliday, RC ;
Jones, BC ;
Park, BK ;
Smith, DA .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1997, 22 (04) :291-294
[6]   Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4 - Role of residues 210 and 211 in flavonoid activation and substrate specificity [J].
Harlow, GR ;
Halpert, JR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (09) :5396-5402
[7]   Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics [J].
Harlow, GR ;
Halpert, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) :6636-6641
[8]  
Ishigami M, 2001, DRUG METAB DISPOS, V29, P282
[9]   Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes [J].
Khan, KK ;
Halpert, JR .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 373 (02) :335-345
[10]   CYCLOSPORINE METABOLISM IN HUMAN-LIVER - IDENTIFICATION OF A CYTOCHROME-P-450III GENE FAMILY AS THE MAJOR CYCLOSPORINE-METABOLIZING ENZYME EXPLAINS INTERACTIONS OF CYCLOSPORINE WITH OTHER DRUGS [J].
KRONBACH, T ;
FISCHER, V ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (06) :630-635